DBV Technologies (DBV) to Present Additional VITESSE Phase 3 Data on Peanut-Allergic Children

DBV Technologies (NASDAQ:DBV) will present additional results from its VITESSE Phase 3 trial evaluating an oral immunotherapy treatment for peanut-allergic children on February 15, 2026. The data will include efficacy and safety endpoints for the full cohort of 600 patients randomized to the treatment arm. The company will also discuss preliminary findings on biomarker response and treatment tolerability. The announcement follows the trial’s positive top-line results released on January 20, 2026.